1. Heterocyclic compounds in design (I), wherein R1 is h, tar, cyclopentyl； R2 is so2r7, C (o) R8, wherein R7 is cyclopentyl or cyclopentyl； R8 is tar, beryllium, etc.； R3 is h, tar or cyclopentyl； R4 is h, halogenated, tar or cyclopentyl； R5 is the optional arilo, replaced by RA and Rb, each of which is h, halogen or halotar. The preferred compound is 1 - (3 - (cyclopropylsulfonyl) phenyl) - 5 - ((2-fluoro-4-iodophenyl) amino) - 6,8-dimethylpyridine-2,4,7 (1H, 3h, 6h) - trinitrocarboxylic acid；3-cycloacrylonitrile-1 - (2-fluoro-4-iodo-phenyl) - 5 - ((3 - (3-hydroxyhydrazine-1-il) phenyl) - 6,8-dimethylpyridine [2,3-d] pyridine-2,4,7 (1H, 3h, 8h) - Trinitromethyl ester, etc. He also mentioned a pharmaceutical composer These compounds are inhibitors of MEK pentagonase, which are useful in the treatment of cancer, psoriasis and restenosis.SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE R1 ES H, ALQUILO, CICLOALQUILO, ENTRE OTROS； R2 ES -SO2R7, -C(O)R8, ENTRE OTROS, EN DONDE R7 ES CICLOALQUILO O CICLOALQUENILO； R8 ES ALQUILO, ALQUENILO, ENTRE OTROS； R3 ES H, ALQUILO O CICLOALQUILO； R4 ES H, HALOGENO, ALQUILO O CICLOALQUILO； R5 ES ARILO OPCIONALMENTE SUSTITUIDO CON Ra Y Rb, EN DONDE Ra Y Rb SON CADA UNO H, HALOGENO O HALOALQUILO. SON COMPUESTOS PREFERIDOS: 1-(3-(CICLOPROPILSULFONIL)FENIL)-5-((2-FLUORO-4-YODOFENIL)AMINO)-6,8-DIMETILPIRIDO[4,3-d]PIRIMIDINA-2,4,7(1H,3H,6H)-TRIONA； 3-CICLOPROPIL-1-(2-FLUORO-4-YODOFENIL)-5-((3-(3-HIDROXIAZETIDIN-1-IL)FENIL)AMINO)-6,8-DIMETILPIRIDO[2,3-d]PIRIMIDINA-2,4,7(1H,3H,8H)-TRIONA； ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA MEK SIENDO UTILES EN EL TRATAMIENTO DE CANCER, PSORIASIS, RESTENOSIS
